多重瓶颈阻碍原料药企业发展——据悉,我国抗生素、维生素C等大宗原料药出口在国际上占绝对优势。但是由于近年来国内原料药行业规模不断扩大,我国原料药低水平重复建设十分普遍,产能过剩问题突出,造成低价竞争、资源浪费,进而形成恶性循环。另外,我国原料药企业一直面临着挥之不去的难题——环保压力。特别是2015年1月1日实施的新环保法,对企业违法的处罚力度加大, Multiple bottlenecks have hindered the development of API companies - it is reported that China’s export of bulk APIs such as antibiotics and vitamin C has an absolute advantage in the international market. However, due to the continuous expansion of the domestic raw material drug industry in recent years, the low-level duplicate construction of raw material drugs in China is very common, and the problem of overcapacity is prominent, resulting in low-price competition and waste of resources, thus creating a vicious circle. In addition, raw material companies in China have faced lingering challenges - environmental pressure. In particular, the new environmental protection law that was implemented on January 1, 2015 increased the penalties for corporate violations.